EWALL-PH OBSERVARTORY 2022
Ewall Obs 2022
AN OBSERVATORY FOR PATIENTS AGED 18 YEARS AND OVER WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+ OR BCR::ABL1+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND TREATED WITH THE COMBINATION OF BCR::ABL1 INHIBITORS AND CHEMOTHERAPY AND/OR CORTICOSTEROIDS AND/OR A MONOCLONAL ANTIBODY.
1 other identifier
observational
100
1 country
23
Brief Summary
An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2024
Longer than P75 for all trials
23 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 15, 2024
CompletedFirst Submitted
Initial submission to the registry
April 4, 2026
CompletedFirst Posted
Study publicly available on registry
July 6, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 15, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
December 31, 2027
July 6, 2026
April 1, 2026
3.4 years
April 4, 2026
July 1, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Overall survival by 12 months
12 months
Secondary Outcomes (10)
overal survival by 36 months
36 months
proportion of complete remission
36 months
the molecular response defined by BCR//ABL1/ABL1 ratio in bone marrow and/or peripheral blood
36 months
the molecular response defined by IGTR quantification proportion in bone marrow and/or peripheral blood
36 months
Event free survival
36 months
- +5 more secondary outcomes
Eligibility Criteria
Acute Lmphoblastic Leukaemia with Philadelphia chromosome or BCR::ABL1 positive
You may qualify if:
- Male or female patients ≥ 18 years
- Philadelphia chromosome or BCR::ABL1 positive acute lymphoblastic leukaemia
- Treatment with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticotherapy and/or a monoclonal antibody
You may not qualify if:
- Patients deceded and having previously refused data collection
- Not included in a prospective clinical trial
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (23)
Groupe hospitalier sud
Amiens, France
CHU Angers
Angers, France
CH de la cote basque
Bayonne, France
CHU Bordeaux
Bordeaux, France
Hopital Militaire Percy
Clamart, France
CHU clermont ferrand
Clermont-Ferrand, France
Centre Hospitalier sud francilien
Corbeil-Essonnes, France
CHU de grenoble
Grenoble, France
CHU Sud Réunion
La Réunion, France
CH Versailles
Le Chesnay, France
CH Le Mans
Le Mans, France
Chu de Lille
Lille, France
Hopital de la conception
Marseille, France
Institut Paoli Calmettes
Marseille, France
CHRU de Nancy
Nancy, France
Centre Antoine Lacassagne
Nice, 06189, France
Hopital Cochin
Paris, France
Hopital necker
Paris, France
Hopital St Louis
Paris, France
CH de Lyon
Pierre-Bénite, France
CH St Etienne
Saint-Etienne, France
ICANS
Strasbourg, France
Hopital de Purpan
Toulouse, France
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Target Duration
- 5 Years
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor
Study Record Dates
First Submitted
April 4, 2026
First Posted
July 6, 2026
Study Start
January 15, 2024
Primary Completion (Estimated)
June 15, 2027
Study Completion (Estimated)
December 31, 2027
Last Updated
July 6, 2026
Record last verified: 2026-04
Data Sharing
- IPD Sharing
- Will not share